This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Stocks Under $5 With Most 'Buy' Ratings

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

7. Paetec Holding (PAET)

Company Profile: Paetec Holding provides data and voice communication services to enterprises and other telecom carriers. The company recently acquired Cavalier Telecom, which has added to sales, but Paetec is still struggling to recover from the recession.

Share Price: $4.44 (June 27)

Stock Performance This Year: 18%

Analyst Consensus: Of the 14 analysts following Paetec, eight have a "buy" rating on the stock and another five say investors should hold shares. One firm has a "sell" rating on the stock. The average price target of $5.93 represents 33% upside potential.

Bullish Case: D.A. Davidson analyst Donna Jaegers wrote in a May 24 research note that the stock's current price undervalues the Paetec's "strong existing customer base and fiber assets. We think PAET is a good value investment at current prices and think the stock can move up from the $6.50 level in the next year," Jaegers wrote.

Jaegers also notes that Paetec's management was upbeat on data center sales during the company's analyst day in May, as the company "has approximately $40 million to $50 million in data center revenues currently and hopes to grow that to $400 million by 2015."

Meanwhile, TheStreet Ratings has a "sell" rating on the communications company, citing "deteriorating net income, generally weak debt management, disappointing return on equity and feeble growth in its earnings per share."

6. Keryx Biopharmaceuticals (KERX - Get Report)

Company Profile: Keryx is a biopharmaceutical company with a focus on products for the treatment of life-threatening diseases, including renal disease & cancer.

Share Price: $4.62 (June 27)

Stock Performance This Year: 1%

Analyst Consensus: Eight analysts have a "buy" rating on Keryx, including those at firms like Oppenheimer and Ladenburg Thalmann. The only other research shop following the company rates the stock a "hold." The average analyst price target of $10 represents potential upside of 103% from current levels.

Bullish Case: Oppenheimer analyst Boris Peaker wrote in a June 7 research note that he is "cautiously optimistic about the ongoing Phase III trial of perifosine in late-stage colorectal cancer," and that his model suggests a price target for Keryx of $8. He bases this target on the assumption that the patent expiration set for July 2013 will be extended by five years to July 2018.

TheStreet Ratings does not cover Keryx Biopharmaceuticals.

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player
3 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AXAS $0.88 10.30%
DRYS $0.11 5.23%
KERX $3.42 5.71%
S $2.66 4.31%
AAPL $93.99 0.31%


Chart of I:DJI
DOW 15,973.84 +313.66 2.00%
S&P 500 1,864.78 +35.70 1.95%
NASDAQ 4,337.5120 +70.6750 1.66%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs